Spermicidal activity of a new contraceptive sponge

Advances in Therapy

Volumn 19, Issue 5, 2002, Pages 219-228

  Ayotte, N ^a   Colin, P ^b  

^a Ctr Hospitalier Reg de la Mauricie   (Canada)

^b Axcan Pharma Inc   (Canada)

Author keywords

Barrier contraception; Benzalkonium chloride; Nonoxynol 9; Postcoital test; Sodium cholate

Indexed keywords

BENZALKONIUM CHLORIDE; NONOXINOL 9; PROTECTAID; SPERMICIDAL AGENT; TODAY;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLPOSCOPY; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; HUMAN; MUCOSA INFLAMMATION; OPEN STUDY; SEXUALLY TRANSMITTED DISEASE;

EID: 0036766485     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850362     Document Type: Article

References (17)

1. Williamson NE, Joanis C. Acceptability of barrier methods for prevention of unwanted pregnancy and infection. In: Mauck CK, Cordero M, Gabelnick HL, et al, eds. Barrier Contraceptives: Current Status and Future Prospects. New York: Wiley-Liss; 1994:53-67.
2. Trussell J. Contraceptive efficacy of barrier contraceptives. In: Mauck CK, Cordero M, Gabelnick HL, et al, eds. Barrier Contraceptives: Current Status and Future Prospects. New York: Wiley-Liss; 1994:17-51.
3. Chermann JC, Barre-Sinoussi F, Henin Y, Marechal V. HIV inactivation by a spermicide containing benzalkonium chloride. AIDS-Forsch. 1987;2:85-86.
4. Cook RL, Rosenberg MJ. Do spermicides containing nonoxynol-9 prevent sexually transmitted infections? A meta-analysis. Sex Transm Dis. 1998;25:144-150.
5. Niruthisard S, Roddy R, Chutivonge S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet. 1992;339:1371-1375.
6. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 1993;4:165-170.
7. Rekart MC. The toxicity and local effects of the spermicide nonoxynol-9. J AIDS. 1992;5:425-426.
8. Stone KM. HIV, other STDs and barriers. In: Mauck CK, Cordero M, Gabelnick HL, et al, eds. Barrier Contraceptives: Current Status and Future Prospects. New York: Wiley-Liss; 1994:203-212.
9. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268:477-482.
10. Psychoyos A. Protectaid, a new vaginal contraceptive sponge with anti-STD properties. In: Mauck CK, Cordero M, Gabelnick HL, et al, eds. Barrier Contraceptives: Current Status and Future Prospects. New York: Wiley-Liss; 1994;265-270.
11. Psychoyos A, Creatsas G, Hassan E, et al. Spermicidal and antiviral properties of cholic acid: Contraceptive efficacy of a new vaginal sponge (Protectaid®) containing sodium cholate. Hum Reprod. 1993;8:866-869.
12. Psychoyos A, Roche D, Gravanis A. Is cholic acid responsible for embryotoxicity of the postreceptive uterine environment? Hum Reprod. 1989;4:832-834.
13. Data on file. Axcan Ltd, Mont-Saint-Hilaire, Québec, Canada.
14. Courtot AM, Nikas G, Gravanis A, Psychoyos A. Effects of cholic acid and Protectaid® formulations on human sperm motility and ultrastructure. Hum Reprod. 1994;9:1999-2005.
15. Guerrero E, Cordero M, Colin P. Cervico-vaginal irritation potential of a new contraceptive sponge in healthy volunteers. Presented at the 15th World Congress on Fertility and Sterility; September 17-22, 1995; Montpellier, France.
16. Ayotte N, Colin P, Saukiol C, et al. The new Protectaid® sponge: a contraceptive device devoid of clinically significant cervico-vaginal irritation. Presented at the XIth International Conference on AIDS; July 1996; Vancouver, Canada.
17. Moghishi KS. Postcoital tests. In: Mauck CK, Cordero M, Gabelnick HL, et al, eds. Barrier Contraceptives: Current Status and Future Prospects. New York: Wiley-Liss; 1994:173-184.